AJP - Endo Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Endocrinol Metab 293: E91-E95, 2007. First published March 20, 2007; doi:10.1152/ajpendo.00024.2007
0193-1849/07 $8.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
293/1/E91    most recent
00024.2007v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zanchi, A.
Right arrow Articles by Burnier, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zanchi, A.
Right arrow Articles by Burnier, M.

Telmisartan prevents the glitazone-induced weight gain without interfering with its insulin-sensitizing properties

Anne Zanchi,1 Abdul G. Dulloo,2 Christine Perregaux,1 Jean-Pierre Montani,2 and Michel Burnier1

1Division of Nephrology and Department of Medicine, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne; and 2Division of Physiology, University of Fribourg, Fribourg, Switzerland

Submitted 11 January 2007 ; accepted in final form 8 March 2007

Glitazones are peroxisome proliferator-activated receptor (PPAR)-{gamma} agonists with powerful insulin-sensitizing properties. They promote the development of metabolically active adipocytes that can lead to a substantial gain in fat mass. Telmisartan is an ANG II type 1 receptor antagonist with partial PPAR-{gamma} agonistic properties. Recently, telmisartan has been reported to prevent weight gain and improve insulin sensitivity in diet-induced obese rodents. The goal of this study was to examine the influence of telmisartan on pioglitazone-induced weight gain and insulin-sensitizing properties in the following two models of insulin resistance: a nongenetic model (high-fat-fed Sprague Dawley rats) and the genetically obese fa/fa Zucker rat. After a 4-wk treatment, the pioglitazone-induced increase in fat mass was modest in the Sprague Dawley rats and severe in the Zucker rats. In both models, these effects were substantially decreased by concomitant treatment with telmisartan. The effects of telmisartan on body weight and fat mass in the Zucker rats were abolished by pair feeding, suggesting that it is the result of a decrease in food intake. Telmisartan did not interfere with the insulin-sensitizing properties of pioglitazone. This study demonstrates that telmisartan attenuates the glitazone-induced increase in fat mass without interfering with its insulin-sensitizing properties.

glitazones; fat; angiotensin II receptor blocker



Address for reprint requests and other correspondence: A. Zanchi, Div. of Nephrology, Rue du Bugnon 17, CHUV, 1011 Lausanne, Switzerland (e-mail: azanchidel{at}hotmail.com)




This article has been cited by other articles:


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
J. C. Russell, S. D. Proctor, S. E. Kelly, and D. N. Brindley
Pair feeding-mediated changes in metabolism: stress response and pathophysiology in insulin-resistant, atherosclerosis-prone JCR:LA-cp rats
Am J Physiol Endocrinol Metab, June 1, 2008; 294(6): E1078 - E1087.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2007 by the American Physiological Society.